Michael Buckley, PhD

Mike is a 35-year biotech veteran with deep experience/expertise in the development and manufacture of monoclonal antibodies, ADCs and radioconjugates for cancer therapy and diagnosis. Trained as an Immunologist, he has provided successful CMC leadership for IND submissions and BLA approvals for multiple programs in several companies. Mike was the CMC lead for Bexxar – an 131I-labeled anti-CD20 Mab approved for the treatment of NHL in 2003. He is experienced in all phases of drug development, having led organizations in activities ranging from preclinical development to commercial manufacturing. As a consultant over the past 6 years, Mike focuses on process development, analytical methods development/qualification and manufacturing in helping clients bring exciting new molecules into the clinic.